Delfi Diagnostics
Develops liquid biopsy tests using fragmentomics to detect lung and other cancers early.
What they do
Delfi Diagnostics develops next-generation liquid biopsy tests utilizing fragmentomics, which analyzes cell-free DNA packaging patterns in blood. The company sells these high-performance, cost-effective screening solutions to clinical laboratories and healthcare systems to detect multiple cancer types at their earliest stages.
The record
- Vertical
- Oncology
- Sub-segment
- Cancer screening and diagnostics
- Product type
- Diagnostics
- Stage
- Series C+
- Headquarters
- Baltimore, United States
- Region
- North America
- Founded
- 2019
- Total funding
- $335M raised
Notable investors: OrbiMed, Cowen Healthcare Investments, F-Prime Capital, Eli Lilly and Company.